Dynavax Technologies Co. (DVAX) Short Interest Update

Share on StockTwits

Dynavax Technologies Co. (NASDAQ:DVAX) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 15,327,587 shares, a growth of 47.5% from the October 15th total of 10,391,487 shares. Approximately 24.7% of the company’s stock are sold short. Based on an average trading volume of 2,066,553 shares, the short-interest ratio is presently 7.4 days.

DVAX has been the subject of several research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research report on Monday, October 1st. Cowen reissued a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research report on Monday, October 22nd. Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, BidaskClub raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $28.00.

Shares of NASDAQ:DVAX opened at $12.09 on Friday. Dynavax Technologies has a 52-week low of $9.63 and a 52-week high of $22.80. The company has a market capitalization of $756.69 million, a PE ratio of -6.99 and a beta of 0.61. The company has a debt-to-equity ratio of 0.76, a current ratio of 8.87 and a quick ratio of 8.67.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative return on equity of 87.67% and a negative net margin of 5,044.85%. The firm had revenue of $1.46 million during the quarter, compared to the consensus estimate of $3.16 million. During the same period in the prior year, the company posted ($0.38) EPS. The firm’s revenue was up 2822.0% on a year-over-year basis. Equities research analysts forecast that Dynavax Technologies will post -2.49 EPS for the current year.

A number of hedge funds have recently bought and sold shares of DVAX. Wells Fargo & Company MN increased its position in Dynavax Technologies by 9.2% during the 1st quarter. Wells Fargo & Company MN now owns 45,516 shares of the biopharmaceutical company’s stock valued at $903,000 after buying an additional 3,834 shares in the last quarter. LPL Financial LLC bought a new position in Dynavax Technologies during the 1st quarter valued at approximately $283,000. Guggenheim Capital LLC increased its position in Dynavax Technologies by 7.2% during the 1st quarter. Guggenheim Capital LLC now owns 112,278 shares of the biopharmaceutical company’s stock valued at $2,228,000 after buying an additional 7,522 shares in the last quarter. Xact Kapitalforvaltning AB bought a new position in Dynavax Technologies during the 1st quarter valued at approximately $200,000. Finally, WINTON GROUP Ltd bought a new position in Dynavax Technologies during the 1st quarter valued at approximately $199,000. 81.48% of the stock is owned by institutional investors.

WARNING: “Dynavax Technologies Co. (DVAX) Short Interest Update” was first published by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://macondaily.com/2018/11/11/dynavax-technologies-co-dvax-short-interest-update.html.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Recommended Story: Return on Equity (ROE)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply